TW201722429A - 醫藥診斷 - Google Patents
醫藥診斷 Download PDFInfo
- Publication number
- TW201722429A TW201722429A TW105139803A TW105139803A TW201722429A TW 201722429 A TW201722429 A TW 201722429A TW 105139803 A TW105139803 A TW 105139803A TW 105139803 A TW105139803 A TW 105139803A TW 201722429 A TW201722429 A TW 201722429A
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer
- patient
- pyridin
- pik3ca
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262620P | 2015-12-03 | 2015-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201722429A true TW201722429A (zh) | 2017-07-01 |
Family
ID=57517943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105139803A TW201722429A (zh) | 2015-12-03 | 2016-12-02 | 醫藥診斷 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180353515A1 (enExample) |
| EP (1) | EP3383391A1 (enExample) |
| JP (1) | JP2018535997A (enExample) |
| KR (1) | KR20180084830A (enExample) |
| CN (1) | CN108366998A (enExample) |
| AU (1) | AU2016362683B2 (enExample) |
| CA (1) | CA3006419A1 (enExample) |
| HK (1) | HK1253737A1 (enExample) |
| IL (1) | IL259716A (enExample) |
| MX (1) | MX2018006777A (enExample) |
| RU (1) | RU2018123524A (enExample) |
| TW (1) | TW201722429A (enExample) |
| WO (1) | WO2017093905A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210355545A1 (en) * | 2018-10-15 | 2021-11-18 | The Johns Hopkins University | Methods and materials for assessing and treating cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005010145A2 (en) | 2003-07-05 | 2005-02-03 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
| ES2537633T3 (es) | 2004-03-02 | 2015-06-10 | The Johns Hopkins University | Mutaciones del gen de PIK3CA en cánceres humanos |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| TWI471134B (zh) | 2007-09-12 | 2015-02-01 | Genentech Inc | 肌醇磷脂3-激酶抑制劑化合物及化療劑之組合及使用方法 |
| CA2701292C (en) | 2007-10-25 | 2015-03-24 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| JP2013545756A (ja) * | 2010-11-16 | 2013-12-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド | 投与および治療方法 |
| MX2014011682A (es) * | 2012-03-29 | 2015-01-22 | Novartis Ag | Diagnostico farmaceutico. |
| EP3842554B1 (en) * | 2014-05-09 | 2022-12-14 | Memorial Sloan Kettering Cancer Center | Biomarkers for response to pi3k inhibitors |
-
2016
- 2016-11-30 HK HK18112889.9A patent/HK1253737A1/zh unknown
- 2016-11-30 JP JP2018528592A patent/JP2018535997A/ja active Pending
- 2016-11-30 AU AU2016362683A patent/AU2016362683B2/en not_active Ceased
- 2016-11-30 US US15/779,873 patent/US20180353515A1/en not_active Abandoned
- 2016-11-30 RU RU2018123524A patent/RU2018123524A/ru not_active Application Discontinuation
- 2016-11-30 WO PCT/IB2016/057208 patent/WO2017093905A1/en not_active Ceased
- 2016-11-30 CA CA3006419A patent/CA3006419A1/en not_active Abandoned
- 2016-11-30 MX MX2018006777A patent/MX2018006777A/es unknown
- 2016-11-30 EP EP16808813.6A patent/EP3383391A1/en not_active Withdrawn
- 2016-11-30 CN CN201680071092.XA patent/CN108366998A/zh active Pending
- 2016-11-30 KR KR1020187015263A patent/KR20180084830A/ko not_active Withdrawn
- 2016-12-02 TW TW105139803A patent/TW201722429A/zh unknown
-
2018
- 2018-05-30 IL IL259716A patent/IL259716A/en unknown
-
2019
- 2019-05-06 US US16/403,817 patent/US20200138824A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3006419A1 (en) | 2017-06-08 |
| CN108366998A (zh) | 2018-08-03 |
| US20200138824A1 (en) | 2020-05-07 |
| AU2016362683A1 (en) | 2018-05-31 |
| RU2018123524A3 (enExample) | 2020-04-02 |
| JP2018535997A (ja) | 2018-12-06 |
| KR20180084830A (ko) | 2018-07-25 |
| US20180353515A1 (en) | 2018-12-13 |
| IL259716A (en) | 2018-07-31 |
| MX2018006777A (es) | 2018-08-01 |
| AU2016362683B2 (en) | 2019-11-07 |
| WO2017093905A1 (en) | 2017-06-08 |
| EP3383391A1 (en) | 2018-10-10 |
| RU2018123524A (ru) | 2020-01-09 |
| HK1253737A1 (zh) | 2019-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240240255A1 (en) | Bicycle conjugates specific for nectin-4 and uses thereof | |
| KR102125496B1 (ko) | 파르네실전달효소 억제제를 이용하여 암환자를 치료하는 방법 | |
| CA2783743C (en) | Phosphatidylinositol-3-kinase pathway biomarkers | |
| US20210349099A1 (en) | Cancer biomarkers and methods of use thereof | |
| CA2846630A1 (en) | Combination treatments comprising c-met antagonists and b-raf antagonists | |
| CN103327976A (zh) | 基于缺氧状态预选受试者以用于治疗性治疗 | |
| KR20170005419A (ko) | Pi3k 억제제 피크틸리시브로 pr-양성 내강 a형 유방암을 치료하는 방법 | |
| JP2024519060A (ja) | ソトラシブ投与レジメン | |
| CA2992945A1 (en) | Combination therapy using pdk1 and pi3k inhibitors | |
| JP2023500950A (ja) | マントル細胞リンパ腫(mcl)対象を特定するための鉄スコアおよびインビトロ方法ならびに治療的使用および方法 | |
| JP6416508B2 (ja) | Nk/t細胞リンパ腫の検査方法 | |
| US20200138824A1 (en) | Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna | |
| McKay et al. | The effect of weight change during treatment with targeted therapy in patients with metastatic renal cell carcinoma | |
| JP2012508019A (ja) | Ablチロシンキナーゼ阻害剤による慢性骨髄性白血病の治療の最適化方法 | |
| Goemans et al. | FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657 | |
| US20250334588A1 (en) | Treating tuberous sclerosis complex-associated diseases | |
| US20230377684A1 (en) | Novel prediction method and gene signatures for the treatment of cancer | |
| KR20250065332A (ko) | 변형된 stk11 활성 또는 발현을 갖는 암을 치료하기 위한 hdac 억제제 | |
| WO2024061634A1 (en) | Prediction of an outcome of a bladder cancer subject | |
| WO2024036114A2 (en) | Combination therapy including cox-2 inhibitor for the treatment of cancer | |
| Dewaele et al. | Co-activated PDGFRA and EGFR are potential therapeutic targets in intimal sarcoma | |
| HK40064367B (en) | Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors | |
| HK40064367A (en) | Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors |